Daniel Edlin built on testimony that demonstrations of Theranos’s technology didn’t always go as planned and in at least one instance prompted the company to tweak what a patient was shown so a result would look more normal.
Daniel Edlin built on testimony that demonstrations of Theranos’s technology didn’t always go as planned and in at least one instance prompted the company to tweak what a patient was shown so a result would look more normal.